Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof of concept study of DRX-065 (Pioglitazone deuterated) for the treatment of non-alcoholic steatohepatitis (NASH)

Trial Profile

A proof of concept study of DRX-065 (Pioglitazone deuterated) for the treatment of non-alcoholic steatohepatitis (NASH)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone deuterated (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2019 According to a Poxel media release, the company is currently finalizing the design of this trial with input from scientific experts, advisors and key opinion leaders.
    • 08 Nov 2019 According to a Poxel media release, the company expects to initiate this study during the second quarter of 2020 in biopsy-proven NASH patient.
    • 05 Nov 2019 According to an Poxel media release, the company is planning to nitiate the next phase of development in the first half of 2020 following the meeting with the U.S. Food and Drug Administration on the 505(b)(2) regulatory pathway.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top